EGFR-IN-69

Cat. No.: HY-150610

CAS No.: 2433837-65-9

Molecular Formula: $C_{31}H_{37}Cl_2N_7O_3S$

Molecular Weight: 658.64

Target: EGFR

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 12.5 mg/mL (18.98 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.5183 mL	7.5914 mL	15.1828 mL
	5 mM	0.3037 mL	1.5183 mL	3.0366 mL
	10 mM	0.1518 mL	0.7591 mL	1.5183 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC_{50} values of 4.3, 6.6 and 25.6 nM against EGFR $^{L858R/T790M/C797S}$, EGFR$^{L858R/T790M}$, and EGFR$^{19del/T790M/C797S}$, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research[1].

IC_{50} & Target				
	EGFR L858R/T790M/C797S	EGFR$^{L858R/T790M}$	EGFR$^{del19\ T790M\ C797S}$	EGFR^{WT}
	4.3 ± 0.9 nM (IC_{50})	6.6 ± 0.8 nM (IC_{50})	25.6 ± 7.5 nM (IC_{50})	816.0 ± 82 nM (IC_{50})

REFERENCES

[1]. Chen H, et al. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem. 2022 May 12;65(9):6840-6858.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA